<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Longevity Review — January 2026</title>
  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  <link href="https://fonts.googleapis.com/css2?family=Hanken+Grotesk:wght@400;500;600&display=swap" rel="stylesheet">
  <style>
    @font-face {
      font-family: 'Copernicus Trial';
      src: url('fonts/CopernicusTrial-Book.ttf') format('truetype');
      font-weight: 400;
      font-style: normal;
    }
    @font-face {
      font-family: 'Copernicus Trial';
      src: url('fonts/CopernicusTrial-Medium.ttf') format('truetype');
      font-weight: 500;
      font-style: normal;
    }

    *, *::before, *::after { margin: 0; padding: 0; box-sizing: border-box; }

    :root {
      --text-primary: #111111;
      --text-secondary: #44403C;
      --text-tertiary: #78716C;
      --bg-primary: #F9F9F9;
      --bg-secondary: #FDFDFD;
      --bg-tertiary: #F7F6F4;
      --bg-hover: #F5F4F3;
      --bg-white: #FFFFFF;
      --bg-accent: #2A8F87;
      --line-subtle: #E8E5E1;
      --line-default: #D5D2CD;
      --chart-primary: #2A8F87;
      --highlight-info: #E3EBF5;
      --serif: 'Copernicus Trial', Georgia, serif;
      --sans: 'Hanken Grotesk', -apple-system, BlinkMacSystemFont, sans-serif;
      --shadow-card: 0 4px 8px rgba(0,0,0,0.04), 0 2px 4px rgba(0,0,0,0.06);
      --shadow-card-hover: 0 8px 16px rgba(0,0,0,0.06), 0 4px 8px rgba(0,0,0,0.04);
      --radius: 24px;
    }

    html { font-size: 16px; scroll-behavior: smooth; }
    body { font-family: var(--sans); background: var(--bg-primary); color: var(--text-primary); line-height: 1.65; -webkit-font-smoothing: antialiased; }

    .nav-bar { display: flex; justify-content: center; align-items: center; gap: 0; background: var(--bg-secondary); border-bottom: none; font-family: var(--sans); font-size: 0.8rem; font-weight: 500; letter-spacing: 0.04em; }
    .nav-bar a { text-decoration: none; color: var(--text-tertiary); padding: 0.7rem 1.5rem; margin: 4px 0; border-radius: 999px; transition: color 0.2s, background 0.2s; }
    .nav-bar a.active { color: var(--text-primary); background: #ECEAE7; }
    .nav-bar a:hover:not(.active) { color: var(--text-secondary); }

    .sector-tabs { display: flex; justify-content: center; gap: 0.5rem; padding: 1rem 1.5rem; background: var(--bg-secondary); flex-wrap: wrap; }
    .sector-tab { font-family: var(--sans); font-size: 0.8rem; font-weight: 500; text-decoration: none; padding: 0.5em 1em; border-radius: 999px; border: none; color: var(--text-secondary); background: var(--bg-secondary); transition: all 0.2s; }
    .sector-tab:hover { background: var(--bg-hover); }
    .sector-tab.active { background: #ECEAE7; color: var(--text-primary); border: none; }

    .masthead { background: transparent; border-bottom: none; position: relative; }
    .masthead-inner { max-width: 900px; margin: 0 auto; padding: 2.5rem 1.5rem 2rem; text-align: center; }
    .masthead .overline { font-size: 0.7rem; font-weight: 500; letter-spacing: 0.02em;  color: var(--text-tertiary); margin-bottom: 0.75rem; }
    .masthead h1 { font-family: var(--serif); font-size: clamp(2rem, 5vw, 3rem); font-weight: 400; color: var(--text-primary); margin-bottom: 0.5rem; }
    .masthead .edition-date { font-size: 0.95rem; font-weight: 500; color: var(--text-secondary); }
    .masthead .edition-sub { font-size: 0.8rem; color: var(--text-tertiary); }
    .divider-bar { width: 60px; height: 3px; background: var(--text-primary); margin: 1rem auto 0; border-radius: 2px; }

    .container { max-width: 900px; margin: 0 auto; padding: 2rem 1.5rem 4rem; }
    .section { margin-bottom: 3rem; }
    .section-header { display: flex; align-items: center; gap: 0.75rem; margin-bottom: 1.5rem; padding-bottom: 0.75rem; border-bottom: none; }
    .section-title { font-family: var(--serif); font-size: 1.35rem; font-weight: 500; color: var(--text-secondary); }

    .stat-grid { display: grid; grid-template-columns: repeat(4, 1fr); gap: 1rem; margin-bottom: 2rem; }
    @media (max-width: 640px) { .stat-grid { grid-template-columns: repeat(2, 1fr); } }
    .stat-card { background: var(--bg-secondary); border-radius: var(--radius); padding: 1.25rem; text-align: center; box-shadow: var(--shadow-card); }
    .stat-value { font-family: var(--serif); font-size: 1.75rem; font-weight: 500; color: var(--chart-primary); }
    .stat-label { font-size: 0.7rem; font-weight: 500; color: var(--text-tertiary); margin-top: 0.35rem;  letter-spacing: 0.05em; }

    .highlight-box { background: var(--highlight-info); border-radius: var(--radius); padding: 1.5rem; margin-bottom: 1.5rem; }
    .highlight-title { font-family: var(--serif); font-weight: 500; font-size: 1.1rem; margin-bottom: 0.75rem; color: var(--text-primary); }
    .highlight-box p { font-size: 1.125rem; color: var(--text-secondary); line-height: 1.6; }
    .highlight-box strong { color: var(--text-primary); }

    .cards { display: grid; gap: 1rem; }
    .card { background: var(--bg-secondary); border-radius: var(--radius); padding: 1.25rem 1.5rem; box-shadow: var(--shadow-card); transition: box-shadow 0.2s, transform 0.2s; }
    .card:hover { box-shadow: var(--shadow-card-hover); transform: translateY(-1px); }
    .card-headline { font-family: var(--serif); font-size: 1.25rem; font-weight: 500; margin-bottom: 0.4rem; color: var(--text-primary); }
    .card-body { font-size: 1.125rem; color: var(--text-secondary); line-height: 1.6; }
    .card-tag { display: inline-block; font-size: 0.65rem; font-weight: 600; letter-spacing: 0.02em;  padding: 0.2em 0.6em; border-radius: 999px; margin-bottom: 0.6rem; background: var(--bg-tertiary); color: var(--text-secondary); }
    .card-meta { font-size: 0.75rem; color: var(--text-tertiary); margin-bottom: 0.5rem; }

    .bottom-line { background: var(--bg-tertiary); border-radius: var(--radius); padding: 2rem; }
    .bottom-line .section-header { border-bottom-color: var(--line-subtle); margin-bottom: 1rem; padding-bottom: 0.5rem; }
    .bottom-line .section-title { color: var(--text-secondary); }
    .bottom-line p { font-family: var(--sans); font-size: 1rem; line-height: 1.75; color: var(--text-secondary); }

    .footer { text-align: center; padding: 2rem 1.5rem 3rem; font-size: 0.75rem; color: var(--text-tertiary); border-top: 1px solid var(--line-subtle); max-width: 900px; margin: 0 auto; }
  </style>
</head>
<body>

  <nav class="nav-bar">
    <a href="live.html">Live</a>
    <a href="index.html">Daily</a>
    <a href="vc-review.html" class="active">Review</a>
    <a href="archive.html">Archive</a>
  </nav>

  <div class="sector-tabs">
    <a href="vc-review.html" class="sector-tab">VC</a>
    <a href="ai-review.html" class="sector-tab">AI</a>
    <a href="longevity-review.html" class="sector-tab active">Longevity</a>
    <a href="health-wellness-review.html" class="sector-tab">Health</a>
    <a href="space-review.html" class="sector-tab">Space</a>
    <a href="energy-review.html" class="sector-tab">Energy</a>
    <a href="sports-entertainment-review.html" class="sector-tab">Sports & Entertainment</a>
  </div>

  <header class="masthead">
    <div class="masthead-inner">
      <div class="overline">Daily intelligence brief</div>
      <h1>Longevity review</h1>
      <div class="edition-date">February 5, 2026</div>
      <div class="edition-sub">Anti-Aging Research · Gene Therapy · Clinical Trials · What to watch</div>
      <div class="divider-bar"></div>
    </div>
  </header>

  <main class="container">

    <section class="section" id="overview">
      <div class="section-header">
        <h2 class="section-title">Market Overview</h2>
      </div>

      <div class="stat-grid">
        <div class="stat-card"><div class="stat-value">150</div><div class="stat-label">Potential Human Lifespan</div></div>
        <div class="stat-card"><div class="stat-value">2030</div><div class="stat-label">Tooth Regen Drug ETA</div></div>
        <div class="stat-card"><div class="stat-value">N-of-1</div><div class="stat-label">First CRISPR Cure (Infant)</div></div>
        <div class="stat-card"><div class="stat-value">24%</div><div class="stat-label">Retatrutide Weight Loss</div></div>
      </div>

      <div class="highlight-box">
        <div class="highlight-title">The Big Story</div>
        <p>2025 was a breakthrough year for longevity science. <strong>FOXO3-modified cells reversed aging signs in primates</strong>, rapamycin showed new power to protect cells, and the first <strong>personalized N-of-1 CRISPR therapy cured an infant</strong> with a rare genetic disease. Nature is now asking: <strong>Could humans live to 150?</strong></p>
      </div>
    </section>

    <section class="section" id="breakthroughs">
      <div class="section-header">
        <h2 class="section-title">Key Breakthroughs</h2>
      </div>

      <div class="cards">
        <article class="card">
          <span class="card-tag">Gene Therapy</span>
          <h3 class="card-headline">First N-of-1 CRISPR Therapy Cures Infant "Baby KJ"</h3>
          <p class="card-body">A baby born with a rare, untreatable genetic disorder faced a lifetime of pain — until CRISPR gene editing changed everything. <strong>Baby KJ was completely cured</strong> through personalized gene therapy, opening new avenues for customized treatments.</p>
        </article>

        <article class="card">
          <span class="card-tag">Anti-Aging</span>
          <h3 class="card-headline">Rapamycin Shows New Power to Protect Cells</h3>
          <p class="card-body">A major discovery is reshaping how scientists think about longevity. Researchers found that rapamycin, long studied for mTOR effects, has <strong>unexpected cell-protective properties</strong> that could boost immune health as we age.</p>
        </article>

        <article class="card">
          <span class="card-tag">Primate Study</span>
          <h3 class="card-headline">FOXO3-Modified Cells Reverse Aging Signs in Primates</h3>
          <p class="card-meta">VitaDAO-backed research</p>
          <p class="card-body">Seeing FOXO3-modified cells actually <strong>reverse aging signs in primates</strong> is mind-blowing. 2025 is shaping up to be a breakthrough year for tackling degenerative diseases.</p>
        </article>

        <article class="card">
          <span class="card-tag">Stem Cells</span>
          <h3 class="card-headline">Stem Cell Therapy Reverses Biological Aging in Blood Cells</h3>
          <p class="card-body">New research shows stem cell therapy can actually <strong>reverse biological aging in blood cells</strong> — potentially meaning faster recovery, stronger immunity, and sustained vitality as we age.</p>
        </article>

        <article class="card">
          <span class="card-tag">Tooth Regeneration</span>
          <h3 class="card-headline">Toregem BioPharma: Tooth Regeneration Drug Phase 3 in 2025</h3>
          <p class="card-body">The tooth regeneration drug from Toregem BioPharma has entered Phase 3 trials in 2025, with projections for <strong>general availability around 2030</strong>. FDA approval for US expected pending successful trials.</p>
        </article>
      </div>
    </section>

    <section class="section" id="gene-therapy">
      <div class="section-header">
        <h2 class="section-title">Gene Therapy Advances</h2>
      </div>

      <div class="cards">
        <article class="card">
          <span class="card-tag">India Innovation</span>
          <h3 class="card-headline">Made-in-India CRISPR: Sickle Cell Therapy at 98% Lower Cost</h3>
          <p class="card-body">India's indigenous CRISPR therapy for sickle cell disease could cost <strong>₹50 lakh (~$60K) vs ₹25 crore ($3M)</strong> elsewhere. India has the 2nd highest patient count globally — this could be transformative.</p>
        </article>

        <article class="card">
          <span class="card-tag">AI + CRISPR</span>
          <h3 class="card-headline">Stanford: AI-Powered CRISPR Speeds Gene Therapy Development</h3>
          <p class="card-body">Stanford Medicine study shows AI is dramatically accelerating CRISPR gene therapy development — <strong>turning "sci-fi into reality"</strong> for genetic disease treatments.</p>
        </article>
      </div>
    </section>

    <section class="section" id="watch">
      <div class="section-header">
        <h2 class="section-title">What to watch Tomorrow</h2>
      </div>

      <div class="cards">
        <article class="card">
          <p class="card-body">
            <strong>Personalized CRISPR Expansion</strong> — Will more N-of-1 therapies follow Baby KJ's success?<br><br>
            <strong>Rapamycin Clinical Trials</strong> — Multiple longevity-focused trials underway<br><br>
            <strong>Toregem Phase 3 Data</strong> — Tooth regeneration milestone approaching<br><br>
            <strong>VitaDAO Funding</strong> — Decentralized longevity research gaining momentum<br><br>
            <strong>Biological Age Tests</strong> — Consumer epigenetic clocks becoming more accurate
          </p>
        </article>
      </div>
    </section>

    <section class="section" id="bottomline">
      <div class="bottom-line">
        <div class="section-header">
          <h2 class="section-title">Bottom line</h2>
        </div>
        <p>Longevity science is accelerating from theoretical to clinical. The first personalized CRISPR cure for a genetic disease is a landmark. FOXO3 modifications reversing aging in primates, rapamycin's expanded applications, and tooth regeneration entering Phase 3 — these are no longer fringe science. Some researchers now believe 150-year lifespans are achievable. The question is shifting from "if" to "when."</p>
        <p style="margin-top: 1rem; font-weight: 600;">The longevity revolution is moving from labs to clinics. Pay attention.</p>
      </div>
    </section>

  </main>

  <footer class="footer">
    <p>Longevity Review · Compiled by Sanbot · January 2026</p>
    <p>Updated daily</p>
  </footer>

</body>
</html>
